Literature DB >> 35350977

Clonal spread of carbapenemase-producing Enterobacteriaceae in a region, China.

Changfu Yin1, Weiwei Yang2, Yuanpeng Lv2, Peng Zhao2, Jiansheng Wang3.   

Abstract

BACKGROUND: The increasing number of carbapenemase-producing Enterobacterales (CPE) has become a serious problem globally. This study aimed to elucidate their geographically epidemiological characteristics.
METHODS: Resistance genes were identified by polymerase chain reaction (PCR) and sequencing. Bacterial genotyping was studied using multilocus sequence typing (MLST) and wzi typing. The transferability of carbapenemase genes was determined by a broth mating method. The relationships between the rates of antimicrobial consumption and the prevalence of CRE were performed by Pearson's or Spearman's correlation analyses.
RESULTS: A total of 930 phenotypically confirmed carbapenem-resistant Enterobacterales (CRE) isolates collected from 19 hospitals were genotypically characterized. K. pneumoniae (KP) and E. coli isolates were 785 (85.14%) and 96 (10.41%) among 922 CPE isolates. Two major carbapenemase genes blaKPC-2 and blaNDM in CPE isolates accounted for 84.6% (n = 780) and 13.77% (n = 127). ST11 comprised 86.83% (633/729) of KPC-2 KP isolates. Different combinations of extended spectrum-β-lactamase (ESBL) genes of blaSHV, blaCTX, and blaTEM were found in KPC-2 producing KP isolates, and blaCTM-M-14/15, blaSHV-11/12 and blaTEM-1 were common ESBL genotypes. The wzi typing method could further subdivide ST11 KP group into at least five subgroups, among which wzi209 (69.83%, 442/633) was the most frequently isolated, followed by wzi141 (25.28%, 160/633). Conjugation assays showed that high conjugation rates were observed in CPE (15.24%, 32/210) for NDM plasmids, but relatively low (8.1%, 17/210) for KPC-2 plasmids. Different STs, different wzis and temperature could influence plasmid conjugation efficiency. No associations between the rates of antibiotics consumption and CPE prevalence were observed. The number of intra-hospital and inter-hospital transfers of CPE patients increased gradually from 18 (17.82%, 101) and 12 (11.88%, 101) in 2015 to 63 (30.73%, 205) and 51 (24.88%, 205) in 2018 (p = 0.016 and p = 0.008), respectively. Evidence-based measures could effectively reduce the prevalence of ST11-wzi209 clone but failed to control the dissemination of ST11-wzi141 KP clone.
CONCLUSIONS: Clonal spread of CPE, especially KPC-2 ST11 KP was the key factor contributing to the CPE increase in the region. Continued vigilance for the importations should be maintained. Coordinated regional interventions are urgently needed to reduce CPE threat.
© 2022. The Author(s).

Entities:  

Keywords:  Carbapenemase-producing; Enterobacterales; Infection control; Patient transfer; ST11; Wzi

Mesh:

Substances:

Year:  2022        PMID: 35350977      PMCID: PMC8962535          DOI: 10.1186/s12866-022-02497-y

Source DB:  PubMed          Journal:  BMC Microbiol        ISSN: 1471-2180            Impact factor:   3.605


  48 in total

Review 1.  Deconstructing the infection control bundles for the containment of carbapenem-resistant Enterobacteriaceae.

Authors:  L Silvia Munoz-Price; John P Quinn
Journal:  Curr Opin Infect Dis       Date:  2013-08       Impact factor: 4.915

2.  Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.

Authors:  Ze-Qing Wei; Xiao-Xing Du; Yun-Song Yu; Ping Shen; Ya-Gang Chen; Lan-Juan Li
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

3.  Development of a multilocus sequence typing scheme for characterization of clinical isolates of Acinetobacter baumannii.

Authors:  Sergio G Bartual; Harald Seifert; Corinna Hippler; M Angeles Domínguez Luzon; Hilmar Wisplinghoff; Francisco Rodríguez-Valera
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

Review 4.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

5.  Fecal carriage of carbapenem-resistant Enterobacteriaceae in a Chinese university hospital.

Authors:  Zhi-chang Zhao; Xiao-hong Xu; Mao-bai Liu; Juan Wu; Juan Lin; Bin Li
Journal:  Am J Infect Control       Date:  2014-05       Impact factor: 2.918

6.  Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.

Authors:  Ryan K Shields; Brian A Potoski; Ghady Haidar; Binghua Hao; Yohei Doi; Liang Chen; Ellen G Press; Barry N Kreiswirth; Cornelius J Clancy; M Hong Nguyen
Journal:  Clin Infect Dis       Date:  2016-09-13       Impact factor: 9.079

7.  wzi Gene sequencing, a rapid method for determination of capsular type for Klebsiella strains.

Authors:  Sylvain Brisse; Virginie Passet; Anita Björk Haugaard; Anamaria Babosan; Najiby Kassis-Chikhani; Carsten Struve; Dominique Decré
Journal:  J Clin Microbiol       Date:  2013-10-02       Impact factor: 5.948

8.  Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae.

Authors:  Sandeep Kochar; Timothy Sheard; Roopali Sharma; Alan Hui; Elaine Tolentino; George Allen; David Landman; Simona Bratu; Michael Augenbraun; John Quale
Journal:  Infect Control Hosp Epidemiol       Date:  2009-05       Impact factor: 3.254

9.  Resistance Phenotype and Molecular Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae Isolates in Shanghai.

Authors:  Wen-Xia Zhang; Hong-You Chen; Chen Chen; Jun-Hao Chen; Fa-Sheng Wan; Ling-Xia Li; Min Chen; Jue Zhang
Journal:  Microb Drug Resist       Date:  2021-07-23       Impact factor: 3.431

10.  Clinical and Molecular Characteristics of Carbapenem-Resistant Hypervirulent Klebsiella pneumoniae Isolates in a Tertiary Hospital in Shanghai, China.

Authors:  Cong Zhou; Qiang Wu; Leqi He; Hui Zhang; Maosuo Xu; Baoyu Yuan; Zhi Jin; Fang Shen
Journal:  Infect Drug Resist       Date:  2021-07-14       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.